StreetAlpha.app
Home › Stocks › SRPT

Sarepta Therapeutics, Inc. (SRPT)

Healthcare
$13.33
▼ −5.93%
LAST CLOSE · NOV 20

Sarepta Therapeutics develops and sells gene therapy and other medicines for genetic diseases. It last closed at $13.33 on Nov 20, down 5.93% on the day. The next earnings report for SRPT is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, SRPT reported EPS of -$0.27 on revenue of $381.4M, with revenue down 4.5% from a year ago. Over its last 8 reports the stock moved an average of 10.3% the session after earnings. Over the last 12 months SRPT insiders bought $0 of stock on the open market and sold $417K, according to SEC Form 4 filings.

AI Auto Pilots
Is SRPT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SRPT.

Key Stats

Last 12 months
Results
Revenue
$2.0B
−18.9% vs a year ago
Net income
−$114.6M
−5.9% margin
EPS (diluted)
−$1.29
Free cash flow
$176.4M
9.0% margin
Valuation
Market cap
$1.4B
107.2M shares
P/E
–
No P/E while losing money
Price to sales
0.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$472.8M
At Sep 30
Debt
$857.4M
At Sep 30
Shareholder equity
$1.5B
Shares outstanding
107.2M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $701.9M$701.9MFY2021FY2022: $933.0M$933.0MFY2022FY2023: $1.2B$1.2BFY2023FY2024: $1.9B$1.9BFY2024FY2025: $2.2B$2.2BFY2025

From SRPT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
-$0.27
Quarter ended Sep 2026
Year ago EPS
-$0.50
Same quarter last year
Revenue
$381.4M
−4.5% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $1.50Dec '24Mar 2025: -$4.60Mar '25Jun 2025: $1.89Jun '25Sep 2025: -$0.50Sep '25Dec 2025: -$3.93Dec '25Mar 2026: $2.88Mar '26Jun 2026: -$0.05Jun '26Sep 2026: -$0.27Sep '26Latest -$0.27
Revenue by quarter
Dec 2024: $658.4MDec '24Mar 2025: $744.9MMar '25Jun 2025: $611.1MJun '25Sep 2025: $399.4MSep '25Dec 2025: $442.9MDec '25Mar 2026: $730.8MMar '26Jun 2026: $401.3MJun '26Sep 2026: $381.4MSep '26Latest $381.4M
How SRPT moved after its last 8 reports
Average move the session after a report ±10.3%
Nov 5, 2026After the close+1.4%
Aug 5, 2026After the close+5.3%
May 6, 2026After the close−9.7%
Feb 25, 2026After the close−8.0%
Jan 12, 2026After the close+1.5%
Nov 3, 2025After the close−33.7%
Jul 16, 2025After the close+19.5%
Feb 26, 2025After the close−3.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SRPTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SRPT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SRPT

Technical Analysis

SRPT · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 27% below its 20 day and 34% below its 50 day average. It is 38% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the 52 week low at $13.25, and the nearest resistance the Pivot at $13.68.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 6.7%/day
Key levels
$24.6852 week high+85.1%
$18.38200 day average+37.9%
$18.19100 day average+36.5%
$17.9050 day average+34.3%
$16.9820 day average+27.4%
$16.69Swing high (Jul 27)+25.2%
$14.11Pivot R1+5.9%
$13.68Pivot+2.6%
$13.33Last close
$13.2552 week low−0.6%
$12.90Pivot S1−3.2%
Indicators
RSI (14)25.36Oversold below 30Oversold
MACD-1.12Below its signal lineBearish
Stochastic1.1Near the bottom of its rangeOversold
ADX (14)24.6Weak trend
Williams %R-98.7Oversold below −80, overbought above −20Oversold
CCI (20)-148.6Oversold below −100, overbought above 100Oversold
Rate of change−25.2%Change over 10 sessionsBearish
ATR (14)$0.90Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SRPT

What happened before

See how SRPT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SRPT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SRPT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SRPTHow many large options trades hit SRPT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SRPT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼136 buying vs 167 selling
  • ▼Held by funds -2.5 pts
  • ▼Funds holding -18
  • ●Superinvestors: 2 added, 2 cut
  • ▲Put/call 5.80 to 0.95
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding313331−5.4%
In funds' top 1000–
Held by funds99.8%102.3%−2.5 pts
New / increased38 / 9847 / 100−7.5%
Reduced / sold out112 / 55119 / 68−10.7%
Put/call ratio0.955.80−83.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SRPT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SRPT Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$417K2 sales · 2 insiders
2025-12 sold $294K2026-03 sold $123KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 12Stephen MayoDirectorSale7,239$17.02$123K
Dec 16, 2025Ian Michael EstepanCOOSale13,187$22.31$294K
Mar 12, 2025Claude NicaiseDirectorSale2,491$99.64$248K
Dec 12, 2024Hans Lennart Rudolf WigzellDirectorSale10,500$124.84$1.3M
Dec 5, 2024Kathryn Jean BoorDirectorSale1,636$125.55$205K
Every insider buy and sale for SRPT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SRPT insider trades →

From SEC Form 4 filings by SRPT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SRPT is in one of them and how their past SRPT trades turned out.

SRPT in the AI portfolios
Loading…

SRPT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SRPT in an article yet. Here's the latest on the wider market.

SRPT in the news

SRPT Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed May 6
Who traded SRPT · since 2019
Latest 5 filings of 17
$1K – $15KTraded Apr 14, 2025Filed May 6, 2025
$1K – $15KTraded Jul 14, 2023Filed Aug 21, 2023
$1K – $15KTraded Jun 13, 2023Filed Jul 11, 2023
$15K – $50KTraded Apr 10, 2023Filed May 19, 2023
$1K – $15KTraded Mar 6, 2023Filed Apr 20, 2023
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CASell$1K – $15KApr 14, 2025May 6, 202522 d
Josh GottheimerD · NJBuy$1K – $15KJul 14, 2023Aug 21, 202338 d
Josh GottheimerD · NJSell$1K – $15KJun 13, 2023Jul 11, 202328 d
Dan GoldmanD · NYSell$15K – $50KApr 10, 2023May 19, 202339 d
Josh GottheimerD · NJBuy$1K – $15KMar 6, 2023Apr 20, 202345 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Sarepta Therapeutics

Sarepta Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts. It develops and sells gene therapy and other medicines for genetic diseases. One of its products, ELEVIDYS, is a gene therapy given to patients through infusion centers. Its customers include patients, specialist physicians, healthcare providers and payers that cover the cost of treatment.

Headquarters
Cambridge, MA
Founded
1980